SCHEMBL299744

SCHEMBL299744

O=C(c1cc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)ccc1F)c1c[nH]c2ncccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 4/20 0.51
NTRK1 P04629 1/20 0.46
BRAF P15056 3/20 0.44
FFAR4 Q5NUL3 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43
SERPINE1 P05121 1/20 0.42
MAP2K1 Q02750 1/20 0.42
HDAC1 Q13547 3/20 0.41
HDAC8 Q9BY41 3/20 0.41
MAPT P10636 1/20 0.41
HTR6 P50406 1/20 0.41
CYP3A4 P08684 1/20 0.41
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298424 0.91 SLC40A1 (0.48) CCR9NTRK1BRAFFABP4FABP5
SCHEMBL298047 0.88 BRAF (0.56) BRAFCYP3A4
SCHEMBL298074 0.88 CLK1 (0.46) BRAFFFAR4FABP4FABP5MAP2K1
SCHEMBL298469 0.87 ALDH1A1 (0.47) CCR9BRAFMAPTCYP3A4
SCHEMBL298193 0.87 CYP2C9 (0.47) CCR9BRAFFFAR4SERPINE1MAP2K1
SCHEMBL298650 0.83 BRAF (0.51) NTRK1BRAFHDAC1HDAC8MAPT
SCHEMBL298860 0.83 CYP3A4 (0.54) BRAFFABP4FABP5MAP2K1CYP3A4
SCHEMBL298904 0.82 CYP3A4 (0.47) BRAFCYP3A4
SCHEMBL297491 0.80 BRAF (0.51) BRAFMAP2K1CYP3A4
SCHEMBL298324 0.80 CYP3A4 (0.47) CCR9BRAFSERPINE1MAP2K1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CCR9 3946/4885NTRK1 1554/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.